Salvinorin a Produces Cerebrovasodilation Through Activation of Nitric Oxide Synthase, ␬ Receptor, and Adenosine Triphosphate–Sensitive Potassium Channel

Total Page:16

File Type:pdf, Size:1020Kb

Salvinorin a Produces Cerebrovasodilation Through Activation of Nitric Oxide Synthase, ␬ Receptor, and Adenosine Triphosphate–Sensitive Potassium Channel Salvinorin A Produces Cerebrovasodilation through Activation of Nitric Oxide Synthase, ␬ Receptor, and Adenosine Triphosphate–sensitive Potassium Channel Diansan Su, M.D., Ph.D.,* John Riley, B.A.,† Willis J. Kiessling, B.A.,† William M. Armstead, Ph.D.,‡ Renyu Liu, M.D., Ph.D.§ ABSTRACT Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/114/2/374/253404/0000542-201102000-00025.pdf by guest on 02 October 2021 What We Already Know about This Topic • Salvinorin A is a nonopioid selective ␬ opioid receptor agonist. Background: Salvinorin A is a nonopioid, selective ␬ opioid– receptor agonist. Despite its high potential for clinical applica- tion, its pharmacologic profile is not well known. In the current study, we hypothesized that salvinorin A dilates pial arteries via What This Article Tells Us That Is New activation of nitric oxide synthase, adenosine triphosphate–sen- • Salvinorin A is an efficacious cerebral vascular dilator in the sitive potassium channels, and opioid receptors. newborn piglet, under normal conditions and with constriction from endothelin and hypocarbia. Methods: Cerebral artery diameters and cyclic guanosine • Salvinorin A acts via the ␬ opioid receptor, nitric oxide gener- monophosphate in cortical periarachnoid cerebrospinal fluid ation, and adenosine triphosphate–sensitive potassium chan- were monitored in piglets equipped with closed cranial win- nel to produce cerebral vasodilatation. dows. Observation took place before and after salvinorin A administration in the presence or absence of an opioid antag- onist (naloxone), a ␬ opioid receptor–selective antagonist istration every 2 min. Vasodilatation and the associated cy- (norbinaltorphimine), nitric oxide synthase inhibitors clic guanosine monophosphate elevation in cerebrospinal (N(G)-nitro-L-arginine and 7-nitroindazole), a dopamine fluid were abolished by preadministration N(G)-nitro-L-ar- ginine, but not 7-nitroindazole. Although naloxone, norbin- receptor D2 antagonist (sulpiride), and adenosine triphos- ϩ phate–sensitive potassium and Ca2 -activated K channel an- altorphimine, and glibenclamide abolished salvinorin A–in- tagonists (glibenclamide and iberiotoxin). The effects of duced cerebrovasodilation, this response was unchanged by salvinorin A on the constricted cerebral artery induced by iberiotoxin and sulpiride. Hypocarbia and endothelin-con- hypocarbia and endothelin were investigated. Data were an- stricted pial arteries responded similarly to salvinorin A, to alyzed by repeated measures ANOVA (n ϭ 5) with statistical the extent observed under resting tone. significance set at a P value of less than 0.05. Conclusions: Salvinorin A dilates cerebral arteries via acti- Results: Salvinorin A induced immediate but brief vasodi- vation of nitric oxide synthase, adenosine triphosphate–sen- ␬ latation that was sustained for 30 min via continual admin- sitive potassium channel, and the opioid receptor. * Visiting Scholar from Department of Anesthesiology, Renji ALVINORIN A is an active component of Salvia divino- Hospital, Shanghai Jiaotong University, School of Medicine, Shang- rum, a perennial herb of the Lamiaceae (mint) family, in- hai, China, and Assistant Professor, † Research Assistant, ‡ Professor, S § Assistant Professor, Department of Anesthesiology and Critical digenous to Mexico. Salvia divinorum has long been tradition- Care, Hospital of University of Pennsylvania, Philadelphia, ally used by local people to produce hallucinogenic experiences Pennsylvania. essential for spiritual divination.1,2 Salvinorin A is a highly effi- Received from the Department of Anesthesiology and Critical cacious, naturally occurring nonpeptide, and it is the only Care, Hospital of University of Pennsylvania, Philadelphia, Pennsyl- ␬ 1,3 vania. Submitted for publication May 20, 2010. Accepted for publi- known nonnitrogenous opioid receptor (KOR) agonist. cation October 12, 2010. Support was provided from institutional Similar to the history of opium, Salvia divinorum is a and/or departmental sources as well as the Foundation for Anes- naturally abundant plant that has been used by human be- thesia Education and Research (Rochester, Minnesota) Grant no. MRTG-02/15/2008, and the National Institutes of Health (Bethesda, ings for recreational purposes for several centuries. Salvinorin Maryland) Grant no. HD57355. A has been proposed as a new opioid receptor agonist for Address correspondence to Dr. Liu: Department of Anesthesiol- clinical use.4–6 However, none of KOR agonists have been ogy and Critical Care, University of Pennsylvania School of Medi- used clinically because of their known adverse effects. Al- cine, 336 John Morgan Building, 3620 Hamilton Walk, Philadelphia, Pennsylvania 19104. [email protected]. Information on pur- though Salvinorin A does not belong to the opioid drug class, chasing reprints may be found at www.anesthesiology.org or on the despite its KOR-agonist properties, it is banned in many masthead page at the beginning of this issue. ANESTHESIOLOGY’s counties and much of the United States. articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue. Unlike the KOR agonists, salvinorin A does not produce 2 Copyright © 2011, the American Society of Anesthesiologists, Inc. Lippincott frank hallucinatory effects, and has no dysphoric actions. Williams & Wilkins. Anesthesiology 2011; 114: 374–9 Many intrinsic characters of the compound (e.g., quick on- Anesthesiology, V 114 • No 2 374 February 2011 CRITICAL CARE MEDICINE set, short-acting sedative effect, no respiratory depression)7–9 mmHg. Artificial CSF was warmed to 37–38°C before applica- make it attractive for use in well-controlled perioperative tion to the cerebral cortical surface. Pial arteries were observed settings. Therefore, its physiologic profile and related mech- with a television camera mounted on a dissecting microscope. anism should be well investigated—especially its effects on Vascular diameter was measured from a video monitor that the central nervous system, including cerebral vasculature in connected the camera with a video microscaler (FOR-A, IV550, normal and pathologic conditions. Although some neuro- Tokyo, Japan). logic effects of salvinorin has been well documented,1,10,11 no data exist for the cerebral vasculature effect of salvinorin A. Experimental Protocols We have demonstrated that other KOR agonists Pial artery diameter (small artery, 120–160 ␮m; arteriole, (dynorphin and U50488) can dilate the pial artery 10,12 50–70 ␮m) was monitored and recorded every half minute through the nitric oxide pathway. In the current Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/114/2/374/253404/0000542-201102000-00025.pdf by guest on 02 October 2021 for 10 min after injection of artificial CSF in the presence or study, we hypothesized that salvinorin A might dilate pial arteries under resting and increased tone conditions in- absence of the investigated drug. In general, the window was duced by hypocarbia or endothelin via activation of nitric flushed in 30 s with 1–2 ml CSF through the port connected oxide synthase, adenosine triphosphate–sensitive potas- into the side of the window. CSF samples were collected for sium (K ) channels, and ␬ receptors. cGMP analysis before medication administration and 10 ATP min afterward. We collected the cerebral cortical periarach- Materials and Methods noid CSF by slowly infusing CSF into one port of the win- dow and allowing the CSF to drip freely into a collection Ն Salvinorin A (purity 98%), sodium nitroprusside (SNP), tube on the opposite port. N(G)-nitro-L-arginine (L-NNA), glibenclamide, iberiotoxin, Responses to salvinorin A (10 nM and 1 ␮M, dissolved cromakalim, calcitonin gene–related polypeptide, NS1619, nal- with alcohol) and SNP (10 nM and 1 ␮M), were obtained in oxone, methionine enkephalin, norbinaltorphimine, 7-nitroi- the absence and presence of L-NNA (1 ␮M), a nitric oxide ndazole, sulpiride, and isoproterenol are obtained from Sigma- synthase (NOS) inhibitor, and 7-nitroindazole (100 nM), an Aldrich (St. Louis, MO). All other chemicals were also obtained antagonist of neuronal NOS (nNOS). from Sigma-Aldrich and were of reagent grade. To distinguish the direct versus permissive role of nitric oxide in the salvinorin A–induced dilation response, pial Animals and Surgery artery diameter changes were recorded after SNP (100 pM), Newborn pigs (aged up to 6 days, 1.3–1.8 kg) of both gen- a subthreshold vascular concentration of a nitric oxide do- ders were used for this study. Protocols were approved by the nor, as well as after L-NNA and salvinorin A coadministra- Institutional Animal Care and Use Committee of the Uni- tion. Also determined were the influences of the following on versity of Pennsylvania (Philadelphia, Pennsylvania). Ani- pial artery response: sulpiride (100 nM), a dopamine recep- mals were induced with isoflurane (1–2 minimum alveolar tor D2 antagonist; glibenclamide (100 nM), a KATP channel ␣ ϩ ϩ concentration) and maintained with -chloralose (80–100 antagonist; iberiotoxin (100 nM), a Ca2 -activated K ⅐ ⅐ mg/kg supplemented with 5 mg kg h IV). Both femoral channel antagonist; cromakalim (1 ␮M); calcitonin gene– arteries were catheterized to monitor blood pressure and ␮ related polypeptide (10 nM and 1 M),aKATP agonist; and ϩ ϩ blood gas. A catheter was inserted into the right femoral vein NS1619 (10 nM and 1 ␮M),aCa2 -activated K channel for medication administration. Animals were ventilated with agonist.
Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Hallucinogens and Dissociative Drugs
    Long-Term Effects of Hallucinogens See page 5. from the director: Research Report Series Hallucinogens and dissociative drugs — which have street names like acid, angel dust, and vitamin K — distort the way a user perceives time, motion, colors, sounds, and self. These drugs can disrupt a person’s ability to think and communicate rationally, or even to recognize reality, sometimes resulting in bizarre or dangerous behavior. Hallucinogens such as LSD, psilocybin, peyote, DMT, and ayahuasca cause HALLUCINOGENS AND emotions to swing wildly and real-world sensations to appear unreal, sometimes frightening. Dissociative drugs like PCP, DISSOCIATIVE DRUGS ketamine, dextromethorphan, and Salvia divinorum may make a user feel out of Including LSD, Psilocybin, Peyote, DMT, Ayahuasca, control and disconnected from their body PCP, Ketamine, Dextromethorphan, and Salvia and environment. In addition to their short-term effects What Are on perception and mood, hallucinogenic Hallucinogens and drugs are associated with psychotic- like episodes that can occur long after Dissociative Drugs? a person has taken the drug, and dissociative drugs can cause respiratory allucinogens are a class of drugs that cause hallucinations—profound distortions depression, heart rate abnormalities, and in a person’s perceptions of reality. Hallucinogens can be found in some plants and a withdrawal syndrome. The good news is mushrooms (or their extracts) or can be man-made, and they are commonly divided that use of hallucinogenic and dissociative Hinto two broad categories: classic hallucinogens (such as LSD) and dissociative drugs (such drugs among U.S. high school students, as PCP). When under the influence of either type of drug, people often report rapid, intense in general, has remained relatively low in emotional swings and seeing images, hearing sounds, and feeling sensations that seem real recent years.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20100227876A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0227876 A1 Rech (43) Pub. Date: Sep. 9, 2010 (54) METHODS OF REDUCING SIDE EFFECTS Publication Classi?cation OF ANALGESICS (51) Int CL A61K 31/485 (2006.01) A61K 31/40 (2006.01) (75) Inventor: Richard H. Rech, Okemos, MI A61K 31/445 (2006-01) (Us) A61K 31/439 (2006.01) (52) US. Cl. ........................ .. 514/282; 514/409; 514/329 (57) ABSTRACT Correspondence Address: The invention provides for compositions and methods of MARSHALL, GERSTEIN & BORUN LLP reducing pain in a subject by administering a combination of 233 SOUTH WACKER DRIVE, 6300 WILLIS mu-opioid receptor agonist, kappal-opioid receptor agonist TOWER and a nonselective opioid receptor antagonist in amounts CHICAGO, IL 60606-6357 (US) effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The inven tion also provides for methods of enhancing an analgesic effect of treatment With an opioid-receptor agonist in a sub (73) Assignee: RECHFENSEN LLP, RidgeWood, ject suffering from pain While reducing an adverse side effect NJ (US) of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment With an opioid receptor agonist in a subject suffering from pain While reduc ing an adverse side effect of the treatment. The invention (21) Appl. No.: 12/399,629 further provides for methods of promoting the additive anal gesia of pain treatment With an opioid-receptor agonist in a subject in need While reducing an adverse side effect of the (22) Filed: Mar.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Opioids and Nicotine Dependence in Planarians
    Pharmacology, Biochemistry and Behavior 112 (2013) 9–14 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Opioid receptor types involved in the development of nicotine physical dependence in an invertebrate (Planaria)model Robert B. Raffa a,⁎, Steve Baron a,b, Jaspreet S. Bhandal a,b, Tevin Brown a,b,KevinSongb, Christopher S. Tallarida a,b, Scott M. Rawls b a Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA b Department of Pharmacology & Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA, USA article info abstract Article history: Recent data suggest that opioid receptors are involved in the development of nicotine physical dependence Received 18 May 2013 in mammals. Evidence in support of a similar involvement in an invertebrate (Planaria) is presented using Received in revised form 18 September 2013 the selective opioid receptor antagonist naloxone, and the more receptor subtype-selective antagonists CTAP Accepted 21 September 2013 (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH )(μ, MOR), naltrindole (δ, DOR), and nor-BNI (norbinaltorphimine) Available online 29 September 2013 2 (κ, KOR). Induction of physical dependence was achieved by 60-min pre-exposure of planarians to nicotine and was quantified by abstinence-induced withdrawal (reduction in spontaneous locomotor activity). Known MOR Keywords: Nicotine and DOR subtype-selective opioid receptor antagonists attenuated the withdrawal, as did the non-selective Abstinence antagonist naloxone, but a KOR subtype-selective antagonist did not. An involvement of MOR and DOR, but Withdrawal not KOR, in the development of nicotine physical dependence or in abstinence-induced withdrawal was thus Physical dependence demonstrated in a sensitive and facile invertebrate model.
    [Show full text]
  • SALVIA DIVINORUM and SALVINORIN a (Street Names: Maria Pastora, Sage of the Seers, Diviner’S Sage, Salvia, Sally-D, Magic Mint) March 2020
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section SALVIA DIVINORUM AND SALVINORIN A (Street Names: Maria Pastora, Sage of the Seers, Diviner’s Sage, Salvia, Sally-D, Magic Mint) March 2020 Introduction: from Mexico and Central and South America. The Internet Salvia divinorum is a perennial herb in the mint family is used for the promotion and distribution of Salvia divinorum. native to certain areas of the Sierra Mazateca region of It is sold as seeds, plant cuttings, whole plants, fresh and Oaxaca, Mexico. The plant, which can grow to over three dried leaves, extract-enhanced leaves of various strengths feet in height, has large green leaves, hollow square stems (e.g., 5x, 10x, 20x, 30x), and liquid extracts purported to and white flowers with purple calyces, can also be grown contain salvinorin A. These products are also sold at local successfully outside of this region. Salvia divinorum has shops (e.g., head shops and tobacco shops). been used by the Mazatec Indians for its ritual divination and healing. The active constituent of Salvia divinorum has been User Population: identified as salvinorin A. Currently, neither Salvia divinorum According to the National Survey on Drug Use and nor any of its constituents, including salvinorin A, are Health (NSDUH), published by SAMHSA, it is estimated that controlled under the federal Controlled Substances Act 5.3 million persons, aged 12 or older, used Salvia divinorum (CSA). in their lifetime in 2016 in comparison to 5.1 million persons a year ago in 2015 and 1.8 million persons a decade ago in Licit Uses: 2006.
    [Show full text]
  • Table of Contents
    TheJournalof VOLUME271 PHARMACOLOGY NUMBER 3 AND EXPERIMENTAL THERAPEUTICS Contents ANTI-INFLAMMATORIES Lecithinized Superoxide Dismutase Enhances Its R. Igarashi, J. Hoshino, A. Ochiai, 1672 Pharmacologic Potency by Increasing Its Cell Membrane Y. Morizawa and Y. Mizushima Affinity ANALGESICS Role of Endogenous Cholecystokinin in the Facilitation of Mu- Florence Noble, Claire Smadja and 1127 Mediated Antinociception by Delta.Opioid Agonists Bernard P. Roques Downloaded from GBR12909 Attenuates Cocaine-Induced Activation of Michael H. Baumann, George U. Char, 1216 Mesolimbic Dopamine Neurons in the Rat Brian R. Dc Costa, Kenner C. Rice and Richard B. Rothman Substance P N-Terminal Metabolites and Nitric Oxide Mediate Julie S. Kreeger, Kelley F. Kitto and 1281 Capsaicin-Induced Antinociception in the Adult Mouse Alice A. Larson Antinociceptive Actions of Dexmedetomidine and the Kappa- Juhana J. Idanpaan-Heikkila, Eija A. Kalso 1306 jpet.aspetjournals.org Opioid Agonist U.5O,488H against Noxious Thermal, and Timo Seppala Mechanical and Inflammatory Stimuli Involvement of NMDA Receptors in Naloxone-Induced Rustam Yu. Yukhananov and 1365 Contractions of the Isolated Guinea Pig ileum after Alice A. Larson Preincubation with Morphine Development of Cross-Tolerance between - Fang Fan, David R. Compton, Susan Ward, 1383 Tetrahydrocannabinol, CP 55,940 and WIN 55,212 Lawrence Melvin and Billy R. Martin at ASPET Journals on October 2, 2021 Antinociceptive and Response Rate-Altering Effects of Kappa Raymond C. Pitts and Linda A. Dykstra 1501 Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys The Influence of Pharmacogenetics on Opioid Analgesia: Jim Cleary, Gerd Mikus, Andrew Somogyi 1528 Studies with Codeine and Oxycodone in the Sprague-Dawley/ and Felix Bochner Dark Agouti Rat Model Selective Antagonism of Opioid Analgesia by a Sigma System Chih-Cheng Chien and 1583 Gavril W.
    [Show full text]
  • Measures and CDS for Safer Opioid Prescribing: a Literature Review
    Measures and CDS for Safer Opioid Prescribing: A Literature Review Measures and CDS for Safer Opioid Prescribing: A Literature Review Executive Summary The U.S. opioid epidemic continues to pose significant challenges for patients, families, clinicians, and public health policy. Opioids are responsible for an estimated 315,000 deaths (from 1999 to 2016) and have caused 115 deaths per day.1 In 2017, the U.S. Department of Health and Human Services declared the opioid epidemic a public health crisis.2 The total economic burden of opioid abuse in the United States has been estimated to be $78.5 billion per year.3 Although providing care for chronic opioid users is important, equally vital are efforts to prevent so-called opioid-naïve patients (patients with no history of opioid use) from developing regular opioid use, misuse, or abuse. However, much remains unclear regarding what role clinician prescribing habits play and what duration or dose of opioids may safely be prescribed without promoting long-term use.4,5 In 2013, ECRI Institute convened the Partnership for Health IT Patient Safety, and its component, single-topic-focused workgroups followed. For this subject, the Electronic Health Record Association (EHRA): Measures and Clinical Decision Support (CDS) for Safer Opioid Prescribing workgroup included members from the Healthcare Information and Management Systems Society (HIMSS) EHRA and the Partnership team. The project was oriented towards exploring methods to enable a synergistic cycle of performance measurement and identifying electronic health record (EHR)/health information technology (IT)–enabled approaches to support healthcare organizations’ ability to assess and measure opioid prescribing.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K
    Grand Valley State University ScholarWorks@GVSU Funded Articles Open Access Publishing Support Fund 9-2018 Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol Sorscha K. Jarman Grand Valley State University, [email protected] Alison M. Haney Grand Valley State University, [email protected] Glenn R. Valdez Grand Valley State University, [email protected] Follow this and additional works at: https://scholarworks.gvsu.edu/oapsf_articles Part of the Chemicals and Drugs Commons ScholarWorks Citation Jarman, Sorscha K.; Haney, Alison M.; and Valdez, Glenn R., "Kappa Opioid Regulation of Depressive-Like Behavior During Acute Withdrawal and Protracted Abstinence from Ethanol" (2018). Funded Articles. 106. https://scholarworks.gvsu.edu/oapsf_articles/106 This Article is brought to you for free and open access by the Open Access Publishing Support Fund at ScholarWorks@GVSU. It has been accepted for inclusion in Funded Articles by an authorized administrator of ScholarWorks@GVSU. For more information, please contact [email protected]. RESEARCH ARTICLE Kappa opioid regulation of depressive-like behavior during acute withdrawal and protracted abstinence from ethanol ¤ Sorscha K. Jarman, Alison M. Haney , Glenn R. ValdezID* Department of Psychology, Grand Valley State University, Allendale, MI, United States of America ¤ Current address: Department of Psychology, Purdue University, West Lafayette, IN, United States of America * [email protected] a1111111111 a1111111111 a1111111111 a1111111111 Abstract a1111111111 The dynorphin/kappa opioid receptor (DYN/KOR) system appears to be a key mediator of the behavioral effects of chronic exposure to alcohol. Although KOR opioid receptor antago- nists have been shown to decrease stress-related behaviors in animal models during acute ethanol withdrawal, the role of the DYN/KOR system in regulating long-term behavioral OPEN ACCESS changes following protracted abstinence from ethanol is not well understood.
    [Show full text]